The global transthyretin amyloidosis treatment market is experiencing significant growth, driven by an aging population, increased disease awareness, and advancements in targeted therapies. Valued at USD 6.94 billion in 2024, the market is projected to reach USD 20.35 billion by 2033, reflecting a robust CAGR of 11.60% from 2025 to 2033. Key growth factors include the adoption of RNA-based drugs, the emergence of combination therapies, and a shift towards patient-centric care models. North America currently leads the market, holding a 46.3% share in 2024, fueled by advanced healthcare infrastructure and regulatory support for rare diseases.
Study Assumption Years
- Base Year: 2024
- Historical Years: 2019–2024
- Forecast Years: 2025–2033
Transthyretin Amyloidosis Treatment Market Key Takeaways
- Market Size Growth: The global ATTR treatment market was valued at USD 6.94 billion in 2024 and is expected to reach USD 20.35 billion by 2033, growing at a CAGR of 11.60%.
- Regional Dominance: North America holds the largest market share at 46.3% in 2024, driven by advanced healthcare systems and early adoption of novel therapies.
- Therapy Segmentation: Targeted therapies dominate with an 85.6% market share in 2024, owing to their effectiveness in addressing disease causality.
- Disease Type: Wild-type amyloidosis accounts for 56.2% of the market in 2024, primarily due to its prevalence among the aging population.
- Distribution Channels: Hospital pharmacies lead with a 48.6% market share in 2024, reflecting their critical role in managing complex treatments.
- Emerging Trends: The market is witnessing a rise in combination therapies and personalized medicine approaches, enhancing treatment efficacy and patient outcomes.
Market Growth Factors
- Emergence of RNA-Based Treatments for ATTR
Thanks to technological breakthroughs, RNA-based therapies are now leading the charge in medicine, particularly for rare genetic disorders like transthyretin (ATTR) amyloidosis. This condition, which stems from misfolded TTR proteins, can now be treated right at its origin. New treatments like patisiran and vutrisiran use an innovative method known as RNA interference (RNAi). These drugs work by delivering small interfering RNA (siRNA) molecules to the liver, where TTR proteins are primarily made. The siRNA molecules bind to and "silence" the messenger RNA (mRNA) that carries the instructions for producing the faulty TTR protein. This targeted approach stops the creation of both normal and mutated TTR proteins, effectively preventing amyloid deposits from forming. It represents a new strategy that not only manages symptoms but also addresses the root cause of the disease.
- Market Impact of Personalized ATTR Therapies
The market for personalized ATTR (transthyretin amyloidosis) therapies is on fire, driven by a mix of factors. There’s a growing appetite for advanced precision drugs as healthcare shifts from generic treatments to more personalized therapies that get to the heart of the disease. Healthcare providers are also stepping up, diagnosing ATTR earlier and using these targeted treatments that deliver better outcomes for patients. The scene is buzzing with innovation and competition, as pharmaceutical companies invest heavily in developing new drug classes like RNA interference (RNAi) therapies and TTR stabilizers. With these new treatments entering the fray, the competitive landscape is evolving, offering patients more choices and reshaping the ATTR therapy market in exciting ways.
- Rising Adoption of Combination Therapies in ATTR
Managing transthyretin amyloidosis (ATTR) is on the rise, with more attention being paid to combination therapies. Unlike monotherapies that focus on just one aspect of the disease, these multi-pronged strategies tackle ATTR's intricate pathology from different angles, which can really help in managing this rare and progressive condition. For instance, a patient might be given a TTR stabilizer like tafamidis to prevent protein misfolding, along with a gene silencer such as patisiran to lower the production of the transthyretin protein itself. The growing role of combination therapy in ATTR treatment is promising, as it aims to enhance patient outcomes by slowing disease progression, alleviating symptoms, and overcoming the limitations of single-drug treatments. This move towards a more comprehensive and tailored approach reflects a deeper understanding of the disease and a commitment to providing better, long-term care for patients.
Request for a sample copy of this report:
https://www.imarcgroup.com/transthyretin-amyloidosis-treatment-market/requestsample
Market Segmentation
Breakup by Therapy:
- Targeted Therapy:
- Vyndaqel/Vyndamax: Tafamidis-based drugs that stabilize transthyretin proteins, slowing disease progression.
- Onpattro: Patisiran, an RNA interference therapy that reduces transthyretin production.
- Amvuttra: Vutrisiran, a next-generation RNAi therapeutic with improved dosing convenience.
- Tegsedi: Inotersen, an antisense oligonucleotide that inhibits transthyretin synthesis.
- Wainua: Eplontersen, a transthyretin-directed antisense oligonucleotide developed for hereditary ATTR.
- Supportive Therapy: Treatments aimed at managing symptoms and improving quality of life.
- Pipeline Therapy: Emerging therapies under clinical development targeting various aspects of ATTR pathology.
Breakup by Type:
- ATTR with Polyneuropathy (ATTR-PN): Characterized by nerve damage leading to sensory and motor impairments; accounts for 78.1% market share in 2024.
- ATTR with Cardiomyopathy (ATTR-CM): Involves heart muscle dysfunction; expected to grow due to increased awareness and improved diagnostics.
Breakup by Disease:
- Hereditary Transthyretin Amyloidosis:
- Polyneuropathy: Genetic mutations leading to nerve damage.
- Cardiomyopathy: Genetic mutations causing heart muscle involvement.
- Mixed Type: Combination of neurological and cardiac symptoms.
- Wild Type Amyloidosis: Non-hereditary form predominantly affecting the elderly; accounts for 56.2% market share in 2024.
Breakup by Distribution Channel:
- Hospital Pharmacies: Primary distribution channel with 48.6% market share in 2024, due to the complexity of treatments and need for specialized care.
- Specialty Pharmacies: Focus on dispensing high-cost, high-complexity medications.
- Retail Pharmacies: Provide accessibility for maintenance medications and follow-up prescriptions.
- Online Pharmacies: Emerging channel offering convenience and broader reach.
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Regional Insights
North America leads the ATTR treatment market, holding a 46.3% share in 2024. This dominance is attributed to advanced healthcare infrastructure, early adoption of innovative therapies, and supportive regulatory frameworks. The United States, in particular, accounts for 78.6% of the North American market, driven by high disease awareness, availability of approved treatments like tafamidis and patisiran, and favorable reimbursement policies
Recent Developments News
In October 2024, Alnylam Pharmaceuticals submitted a supplemental New Drug Application to the U.S. FDA for vutrisiran (Amvuttra) to treat ATTR amyloidosis with cardiomyopathy, expanding its therapeutic indications. Additionally, in September 2024, AstraZeneca's rare disease division, Alexion, received fast track designation from the FDA for ALXN2220, a treatment aimed at managing transthyretin amyloidosis with cardiomyopathy . These developments underscore the ongoing innovation and regulatory support in the ATTR treatment landscape.
Key Players
Akcea Therapeutics, Inc, Alnylam Pharmaceuticals, Inc., AstraZeneca, BridgeBio, Inc., Intellia Therapeutics, Inc, Pfizer Inc, etc.
Ask Analyst for Customization:
https://www.imarcgroup.com/request?type=reportid=27702flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include a thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape, and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: (+1-201971-6302)
